AR122456A2 - Tetrahidro-pirido[3,4-b]indoles moduladores de receptores de estrógenos y usos de los mismos - Google Patents

Tetrahidro-pirido[3,4-b]indoles moduladores de receptores de estrógenos y usos de los mismos

Info

Publication number
AR122456A2
AR122456A2 ARP210101150A ARP210101150A AR122456A2 AR 122456 A2 AR122456 A2 AR 122456A2 AR P210101150 A ARP210101150 A AR P210101150A AR P210101150 A ARP210101150 A AR P210101150A AR 122456 A2 AR122456 A2 AR 122456A2
Authority
AR
Argentina
Prior art keywords
pyrido
tetrahydro
modulators
indols
estrogen receptors
Prior art date
Application number
ARP210101150A
Other languages
English (en)
Inventor
Simon Charles Goodacre
Sharada Labadie
Jun Liang
Daniel Fred Ortwine
Nicholas Charles Ray
Xiaojing Wang
Jason Zbieg
Birong Zhang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR122456A2 publication Critical patent/AR122456A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se describen compuestos tetrahidro-pirido[3,4-b]indol1-ilo con actividad o función de modulación de los receptores de estrógenos modulación, que tienen la estructura de la fórmula (1), y los estereoisómeros, tautómeros o sales farmacéuticamente aceptables de los mismos, con los sustituyentes y características estructurales aquí descritos. Se describen también composiciones farmacéuticas y medicamentos que incluyen los compuestos de la fórmula (1), así como métodos de uso de tales moduladores de receptores de estrógenos, solos o en combinación con otros agentes terapéuticos, para tratar enfermedades o estados patológicos que están mediados o dependen de receptores de estrógenos.
ARP210101150A 2014-12-18 2021-04-28 Tetrahidro-pirido[3,4-b]indoles moduladores de receptores de estrógenos y usos de los mismos AR122456A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462093929P 2014-12-18 2014-12-18

Publications (1)

Publication Number Publication Date
AR122456A2 true AR122456A2 (es) 2022-09-14

Family

ID=58672209

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP150104155A AR103081A1 (es) 2014-12-18 2015-12-17 Tetrahidro-pirido[3,4-b]indoles moduladores de receptores de estrógenos y usos de los mismos
ARP210101150A AR122456A2 (es) 2014-12-18 2021-04-28 Tetrahidro-pirido[3,4-b]indoles moduladores de receptores de estrógenos y usos de los mismos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP150104155A AR103081A1 (es) 2014-12-18 2015-12-17 Tetrahidro-pirido[3,4-b]indoles moduladores de receptores de estrógenos y usos de los mismos

Country Status (2)

Country Link
AR (2) AR103081A1 (es)
MA (1) MA41172B1 (es)

Also Published As

Publication number Publication date
AR103081A1 (es) 2017-04-12
MA41172B1 (fr) 2020-09-30

Similar Documents

Publication Publication Date Title
CO2017003070A2 (es) Tetrahidro-pirido[3,4-b]indoles moduladores de receptores de estrógenos y usos de los mismos
CR20170563A (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso.
NI201900039A (es) Derivados de 6, 7, 8, 9-tetrahidro-3h-pirazolo[4, 3-f] isoquinolina útiles en el tratamiento del cáncer
PE20151416A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos
CO2018013747A2 (es) Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos
BR112015020389A2 (pt) compostos carbazol úteis como inibidores de bromodomínio
CL2019000245A1 (es) Moduladores nmda espiro-lactam y métodos de uso de los mismos.
MX2018009257A (es) Derivados de benzimidazol como moduladores de ror-gamma.
PE20151436A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos
EA201591403A1 (ru) Спиролактамные модуляторы рецептора nmda и их применение
CL2019000248A1 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos
CO6771417A2 (es) Antagonistas del receptor de ácido lisofosfatidico y su uso en el tratamiento de fibrosis
CO2019010078A2 (es) Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1
CL2019000249A1 (es) Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos.
PE20151438A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos
CL2019000246A1 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos.
CL2019000247A1 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos.
PE20151427A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos
CL2015000039A1 (es) Derivados estra-1,3,5(10),16-tetraeno-3-sustituidos, preparaciones farmacéuticas que los comprenden y su uso en la preparación de medicamentos para tratar la endometriosis.
UY33490A (es) Ésteres de quinolina nuevos útiles para el tratamiento de trastornos cutáneos.
CL2017002605A1 (es) Derivados de indol
AR122456A2 (es) Tetrahidro-pirido[3,4-b]indoles moduladores de receptores de estrógenos y usos de los mismos
UY36958A (es) Compuestos para administración intracelular
EA202192092A2 (ru) ТЕТРАГИДРОПИРИДО[3,4-b]ИНДОЛОВЫЕ МОДУЛЯТОРЫ ЭСТРОГЕНОВЫХ РЕЦЕПТОРОВ И ИХ ПРИМЕНЕНИЕ